OBJECTIVES: In a previous study, we determined the costs over 6 months to the French public health insurance system of Hylan GF-20 (Synvisc) in 66 @entity1 with @entity626 . Here, we compared the medicoeconomic benefits over 9 months in 506 @entity1 given Hylan GF-20 or conventional treatment for @entity626 . @entity1 AND METHODS: This prospective randomized study was conducted from October 1998 to February 2000. Clinical status was evaluated using the Lequesne index, the WOMAC index, and the SF12 quality-of-life questionnaire. Medical and sick leave costs to the public health insurance system were determined. RESULTS: Effectiveness criteria were evaluable in all 506 @entity1 . Significant clinical improvements were noted from the first month to the end of the 9-month study period in the Synvisc group. A mean 2-point difference in the Lequesne index area-under-the-curve was found in favor of Synvisc (P < 0.0001). Mean medical and sick leave costs per @entity1 over 9 months were 829.10 in the Synvisc group and 829.40 in the conventional treatment group. CONCLUSION: This study carried out over 9 months in a large population confirms that Synvisc viscosupplementation is more effective than conventional treatment, at no additional cost. It takes a step toward answering the request of international experts for medicoeconomic data on viscosupplementation for @entity571 .

Prospective randomized study comparing the medicoeconomic benefits of Hylan GF-20 vs. conventional treatment in XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity626 :: ('MESH:D020370', 'Disease') :: ['knee osteoarthritis'] @entity571 :: ('MESH:D010003', 'Disease') :: ['osteoarthritis']
@entity626 :: (MESH:D020370,Disease) :: ['knee osteoarthritis']
